Overview

Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).

Phase:

PHASE3

Details

Lead Sponsor:

Marmara University

Collaborator:

Health Institutes of Turkey

Treatments:

Immune Tolerance
Immunosuppression Therapy
Rivaroxaban